Select a location
Sunshine Coast
Learn more or register for a clinical trial currently underway at our Sippy Downs and Birtinya clinics
Moreton Bay
Learn more or register for a clinical trial currently underway at our Morayfield clinic
Brisbane
Learn more or register for a clinical trial currently underway at our South Bank clinic
Specialist cancer trials
Learn more or register for a specialist cancer clinical trial currently underway at our Buderim clinic, run through the Sunshine Coast Haematology and Oncology Clinic
Frequently asked questions
Got a question about clinical trials? Get answers here.
Featured trials
Completed studies
When available, the results of studies completed by UniSC Clinical Trials are listed below.
| Protocol Number | Protocol | Results Available? |
| 205715 | A Phase III, randomized, double-blind, active controlled, parallel group study, comparing the efficacy, safety and tolerability of the fixed dose combination FF/UMEC/VI with the fixed dose dual combination of FF/VI, administered once-daily via a dry powder inhaler in subjects with inadequately controlled asthma | |
| 200812 | A Phase III, 4-week, randomised, double-blind study to compare ‘closed’ triple therapy (FF/UMEC/VI), 'open' triple therapy (FF/VI + UMEC) and dual therapy (FF/VI) in subjects with chronic obstructive pulmonary disease (COPD) | Results Available |
| RTB-101-204 | A Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Determine if RTB101 Prevents Symptomatic Respiratory Illness Associated with Laboratory-Confirmed Pathogens in the Elderly | Results Pending |
| FBP-001 | A phase I/II study of povidone-iodine nasal spray (“Nasodine”) to investigate safety and tolerability in healthy volunteers (Stage 1), and to investigate safety and efficacy in patients with the common cold (Stage 2). | Results Pending |
| FBP-002 | A phase III study of the safety and efficacy of povidone-iodine nasal spray (“Nasodine”) in the treatment of subjects with the common cold in the natural setting. | Results Pending |
| Protocol Number | Protocol | Results Available? |
| FLU-AUS-1701 | A Prospective Multi-Centre Study of the ellume·lab Flu A+B Test and iTreat Flu A+B Flu Test Performance versus Viral Culture and Reverse Transcriptase Polymerase Chain Reaction. | Results Pending |
| RESP16001 | A PROSPECTIVE MULTI-CENTRE STUDY OF THE RESPIRIO FLU TEST AND eLab FLU TEST PERFORMANCE VERSUS REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION (RT-PCR) FOR THE RAPID DETECTION OF INFLUENZA A/B. | Results Pending |
| GAS-AUS-1701 | A PROSPECTIVE MULTI-CENTRE STUDY OF THE PERFORMANCE OF THE ELLUME·LAB GROUP A STREP TEST VERSUS CULTURE FOR THE RAPID DETECTION OF GROUP A STREPTOCOCCUS IN PARTICIPANTS WITH ACUTE PHARYNGITIS | Results Pending |
| Protocol Number | Protocol | Results Available? |
| RPC01-3202 | INDUCTION STUDY #2 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE | Results Pending |
| GS-US-419-3895 | Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease | Results Pending |
| GS-US-419-3896 | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease | Study Ongoing |
| GA29144 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE | Study Ongoing |
| GA29145 | AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144 | Study Ongoing |
| GS-US-418-3898 | Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Ulcerative Colitis | Results Available |
| GS-US-418-3899 | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis | Results Available |
| Protocol Number | Protocol | Results Available? |
| SHP640-301 | A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640(PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis | Results Available |
| SHP640-303 | A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640(PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis | Results Available |
| P2-868963_001 | A Multicenter, Prospective, Randomized, Double- Masked, Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of Topical AG-86893 in Patients with Pterygium |
| Protocol Number | Protocol | Results Available? |
| 1002-043 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT | |
| 1245-0167 | A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on Exercise ability and heart failure symptoms, In patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF) (EMPERIAL – preserved) | Results Available |
| 1245-0168 | A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on Exercise ability and heart failure symptoms, In patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF) (EMPERIAL – reduced) | |
| AROAPOC31001 | A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as well as in Severely Hypertriglyceridemic Patients and Patients with Familial Chylomicronemia Syndrome |
| Protocol Number | Protocol | Results Available? |
| BIVV009-03 | A PHASE 3 PIVOTAL, OPEN-LABEL,MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WHO HAVE A RECENT HISTORY OF BLOOD TRANSFUSION | Results Pending |
| BIVV009-04 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WITHOUT A RECENT HISTORY OF BLOOD TRANSFUSION | Study Ongoing |
| Protocol Number | Protocol | Results Available? |
| V160-002 | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3- Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35 Years of Age | Results Pending |
| FLU009 | A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults aged 18 years and over | |
| V199_04 | A Phase IIIb-IV, Multicentre, Randomised, Open-label Study to Characterise the Reactogenicity of Afluria Quad Junior in Children 6 Months to Less Than 3 Years, and Afluria Quad in Children 3 Years to Less Than 9 Years Across Three Influenza Seasons | |
| 2019nCoV-101 | A 2-PART, PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A SARS-CoV-2 RECOMBINANT SPIKE PROTEIN NANOPARTICLE VACCINE (SARS-CoV-2 rS) WITH OR WITHOUT MATRIX-M™ ADJUVANT IN HEALTHY SUBJECTS |
|
| V201_01 | A Phase 2, Randomized, Observer-Blind, Antigen and Adjuvant Dose-Ranging Clinical Study to Evaluate Safety and Immunogenicity of Different Formulations of MF59-Adjuvanted Quadrivalent Subunit Inactivated Cell-derived Influenza Vaccine |
| Protocol Number | Protocol | Results Available? |
| MT14-AU18GBL208 | Phase II, Randomized, Double-Blind, Placebo Controlled, Multi-Center, Dose-ranging and Open Label Extension Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Moderate to Severe Glabellar Lines | Study Ongoing |
| MT14-AU18LCL209 | Phase , Randomized, Double-Blind, Placebo Controlled, Multi-Center, Dose-ranging and Open Label Extension Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Moderate to Severe Lateral Canthal Lines | Study Ongoing |
| Protocol Number | Protocol | Results Available? |
| ZYN2-CL-005 | A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multiple Center, Multiple-Dose Study to Assess the Efficacy and Safety of ZYN002 Administered as a Transdermal Gel to Patients with Knee Pain due to Osteoarthritis | Results Pending |
| Sub-001 | A Randomised, Double-blind, Placebo Controlled Study to Investigate the Efficacy on Pain Reduction and Safety of Swisse High Strength Deep Sea Krill Oil (Superba BOOST) in Adults with Mild to Moderate Osteoarthritis of the Knee | Results Pending |
| Protocol Number | Protocol | Results Available? |
| ZYN2-CL-03 | A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre, Multiple-Dose Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Patients with Partial Onset Seizures, Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy (STAR 1) | Results Pending |
| ZYN2-CL-004 | Open Label Extension Study to ZYN2-CL-03 to Assess the Long Term Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Patients with Partial Onset Seizures (STAR 2) | Results Pending |
| Protocol Number | Protocol | Results Available? |
| Nexvax2-1005 | A BIOEQUIVALENCE STUDY OF NEXVAX2 IN HLA-DQ2.5+ ADULTS WITH CELIAC DISEASE | |
| Nexvax2-2006 | A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN HLA-DQ2.5+ ADULTS WITH CELIAC DISEASE TO ASSESS THE EFFECT OF NEXVAX2 ON SYMPTOMS AFTER MASKED GLUTEN FOOD CHALLENGE | |
| CDX6114-002 | A Phase 1, Multi-center, Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of a Single Oral Dose of CDX-6114 in Patients with Phenylketonuria (PKU). |
| Protocol Number | Protocol | Results Available? |
| ML-004-ER-001 | A PHASE 1 OPEN LABEL CROSSOVER STUDY OF ML-004-ER UNDER FASTED AND FED CONDITIONS IN ADULT HEALTHY VOLUNTEERS |
Results Pending |